Although the majority of U.S.-based cannabis companies and many foreign ADRs trade over-the-counter, a few marijuana companies are traded on the NASDAQ. Some investors prefer stocks that are listed on the NASDAQ to other exchanges due to their increased liquidity and tighter spreads than the OTC markets. Indeed, as the cannabis industry has grown in recent months and years, uplisting from an OTC market to a reputable U.S. exchange has become a banner achievement for many rising marijuana companies.
The NASDAQ was the first electronic exchange and has long been synonymous with technology and biotechnology. The cannabis companies on the NASDAQ reflect this, with the majority of them operating in the biotech area of the industry. Here are the NASDAQ-listed marijuana stocks, in alphabetical order, as of Oct. 9, 2018, with a breakdown of their total returns.
The NASDAQ was the first electronic exchange and has long been synonymous with technology and biotechnology. The cannabis companies on the NASDAQ reflect this, with the majority of them operating in the biotech area of the industry. Here are the NASDAQ-listed marijuana stocks, in alphabetical order, as of March 5, 2019, with a breakdown of their total returns.
Arena Pharmaceuticals is a biotech company involved in the manufacturing of medical marijuana drugs. Research and development around Arena's APD371 is the primary focus of its cannabis biotech initiatives.
Atlantic Alliance Partnership Corp. is a blank check company that is currently in a merger agreement with Kalyx Development Inc. Kalyx is a leading real estate investment trust in the regulated cannabis industry in the U.S.
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities for the indications of pain and pruritus (itching). Although all of their clinical-stage products target opioid receptors, Cara is currently conducting preclinical research on cannabinoids for the treatment of neuropathic pain.
Corbus Pharmaceuticals Holdings Inc. is a cannabis biotech company. Its research, development, and manufacturing are based around cannabis drugs that seek to treat chronic, inflammatory, fibrotic and other diseases.
Cronos Group Inc. is a Canadian cannabis company. It owns and seeks cannabis related subsidiaries and licensed producers. In December of 2018, Marlboro maker Altria announced plans to invest $1.8 billion in Cronos. The investment has provided Cronos not only with additional cash to finance its continued expansion, but also with a well-established partner experienced in the process of marketing consumer brands.
GW Pharmaceuticals is developing a portfolio of cannabinoid medicines, including Sativex for the treatment of spasticity related to multiple sclerosis and cancer pain, and Epidiolex for the treatment of childhood epilepsy. Sativex is commercialized in more than a dozen countries outside the U.S. and has received regulatory approval in several more countries. Epidiolex received FDA approval as a treatment for Dravet Syndrome and Lennox-Gastaut Syndrome, two forms of severe, early onset epilepsy without good existing treatment options. Other indications show that GW Pharmaceuticals is developing cannabinoid products for autism spectrum disorders, schizophrenia and glioma.
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems. Though the company is more widely known for its Subsys fentanyl spray, Insys has received FDA approval for a dronabinol (synthetic THC) oral solution for the treatment of nausea caused by chemotherapy and anorexia in patients with AIDS. Insys is also developing cannabinoid-based treatments for epileptic disorders, Prader-Willi Syndrome (a genetic disorder) and amphetamine addiction among other indications.
Intec Pharma is a clinical-stage biopharmaceutical company that is developing drugs based on its proprietary Accordion Pill technology. Intec's product pipeline includes cannabinoid-based drugs being developed for the indications of low back pain and fibromyalgia.
Marrone Bio Innovations, Inc. develops and distributes environmentally responsible bio-based pest management and plant health products. Just recently, Marrone Bio Innovations announced that three MBII active ingredients are now legal for use on cannabis crops in the California cultivation market.
Psychemedics Corporation operates in the enforcement sector. Its business operations support drug testing through hair samples.
Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company focused on the development of cannabinoid-based drugs. Therapix's current pipeline includes products targeted for the treatment of Tourette syndrome and mild cognitive impairment.
Tilray Inc. was the first marijuana-related company to IPO in the U.S. The Nanaimo, Vancouver Island-based company focuses on medical cannabis products.
Village Farms International is the most recent cannabis stock to begin trading on the NASDAQ. VFF shares became available for trade on February 21, 2019. The company has a decades-long history in greenhouse produce growing and has only recently shifted some of its focus toward cannabis production.
虽然大多数美国的大麻公司和许多外国的 ADR 都在场外交易，但一些大麻公司在纳斯达克交易。一些投资者更喜欢在纳斯达克（ NASDAQ ）上市的股票，而不是其他交易所，因为它们的流动性增加，息差比非处方药（OTC）市场收窄。事实上，随着大麻行业在最近几个月和几年的发展，从非处方药（OTC）市场升级到著名的美国交易所已经成为许多大麻公司的一项重大成就。
纳斯达克是第一个电子交易所，长期以来一直是技术和生物技术的代名词。纳斯达克（ NASDAQ ）上的大麻公司反映了这一点，其中大多数公司在该行业的生物技术领域经营。以下是纳斯达克上市的大麻股票，按字母顺序排列，截至2018年10月9日，其总回报的明细。
纳斯达克是第一个电子交易所，长期以来一直是技术和生物技术的代名词。纳斯达克（ NASDAQ ）上的大麻公司反映了这一点，其中大多数公司在该行业的生物技术领域经营。以下是纳斯达克上市的大麻股票，按字母顺序排列，截至2019年3月5日，其总回报的明细。
Arena Pharmaceuticals 是一家从事医用大麻药品生产的生物技术公司。围绕阿雷纳 APD371的研发是其大麻生物技术计划的主要重点。
大西洋联盟合伙公司( Atlantic Alliance Partnership Corp .)是一家空白支票公司，目前正与 Kalyx Development Inc .达成合并协议。
Cara Therapeutics 是一家临床阶段的生物技术公司，专注于开发和商业化用于疼痛和瘙痒（瘙痒）适应症的新化学实体。尽管他们所有的临床阶段产品都以阿片类药物受体为靶点， Cara 目前正在进行大麻素的临床前研究，用于治疗神经病理性疼痛。
Corbus Pharmaceuticals Holdings Inc .是一家大麻生物技术公司。其研究、开发和制造基于大麻药物，寻求治疗慢性、炎症性、纤维性和其他疾病。
Cronos Group Inc .是一家加拿大大麻公司。它拥有和寻求大麻相关的子公司和特许生产商。2018年12月，万宝路制造商奥驰亚宣布计划向克罗诺斯投资18亿美元。这笔投资不仅为 Cronos 提供了额外的现金，为其持续扩张提供资金，而且还为其提供了一个在销售消费者品牌过程中经验丰富的合作伙伴。
GW 制药正在开发一系列大麻药物，包括用于治疗多发性硬化症和癌症疼痛相关的痉挛的 Sativex ，以及用于治疗儿童癫痫的 Epdiolex 。Sativex 在美国以外的十几个国家实现了商业化，并在多个国家获得了监管机构的批准。Epidiolex 获得 FDA 批准作为治疗 Draft 综合征和 Lennox-Gastaut 综合征的药物，这两种形式严重，早期发作的癫痫没有良好的现有治疗方案。其他迹象显示， GW 制药正在开发针对自闭症谱系障碍、精神分裂症和神经胶质瘤的大麻素产品。
Insys Therapeutics 是一家专业制药公司，开发和商业化创新药物和新型药物输送系统，尽管该公司以其 Subys 芬太尼喷雾产品而闻名。因治疗艾滋病患者化疗和厌食症引起的恶心， Insys 公司已经获得 FDA 批准的一种口服罗那滨（合成 THC ）溶液。Insys 还正在开发基于大麻的治疗癫痫病，普拉德-威利综合征（一种遗传性疾病）和安非他明成瘾的其他迹象。
英特药业是一家临床阶段的生物制药公司，正在开发基于其专有的 Accordion 丸技术的药物。Intc 的产品管线包括正在开发的用于显示腰痛和纤维肌痛的大麻为基础的药物。
Marrone Bio Innovations , Inc .开发和分销对环境负责的生物害虫管理和植物健康产品。就在最近， Marrone 生物创新公司宣布三种 MBII 活性成分现在在加州种植市场上合法用于大麻作物。
Therpix Biosciences Ltd .是一家专注于大麻素类药物研发的专业临床阶段制药企业。治疗药物目前的管道包括治疗图雷特症和轻度认知障碍的产品。
Tilray Inc .是首家在美国上市的大麻相关公司。总部位于温哥华的 Nanaimo 公司专注于医用大麻产品。